SPOTLIGHT: Actavis bids $1.6 billion for Pliva
In a new sign of the ongoing consolidation of the global generic drug business, Iceland's Actavis has bid $1.6 billion to buy Pliva. If successful, a merger would create the third largest generic drug company in the world. Pliva shareholders will now have to consider a bid of $94.31 a share, a 34 percent premium of Pliva's three-month average. Release
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
